|Other Names||Cytoplasmic protein NCK2, Growth factor receptor-bound protein 4, NCK adaptor protein 2, Nck-2, SH2/SH3 adaptor protein NCK-beta, NCK2, GRB4|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP14107a was selected from the N-term region of NCK2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Adapter protein which associates with tyrosine- phosphorylated growth factor receptors or their cellular substrates. Maintains low levels of EIF2S1 phosphorylation by promoting its dephosphorylation by PP1. Plays a role in ELK1- dependent transcriptional activation in response to activated Ras signaling.|
|Cellular Location||Cytoplasm. Endoplasmic reticulum|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the NCK family of adaptorproteins. The protein contains three SH3 domains and one SH2domain. The protein has no known catalytic function but has beenshown to bind and recruit various proteins involved in theregulation of receptor protein tyrosine kinases. It is throughthese regulatory activities that this protein is believed to beinvolved in cytoskeletal reorganization. Alternate transcriptionalsplice variants, encoding different isoforms, have beencharacterized.
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Guan, S., et al. J. Invest. Dermatol. 129(8):1909-1920(2009)Liu, J., et al. PLoS ONE 4 (11), E7805 (2009) :Akiyama, M., et al. Br J Ophthalmol 92(9):1293-1296(2008)Park, S., et al. J. Biomol. NMR 34(3):203-208(2006)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.